Exciting Announcement! We're thrilled to announce that today, April 1st, 2024, Viroclinics-DDL is now Cerba Research! As part of Cerba Research since 2022, we're embarking on the next phase of our journey by consolidating Viroclinics-DDL under a single, dynamic brand. This rebranding signifies our unwavering commitment to advancing clinical research collectively. Our new identity underscores our dedication to accelerating the development of life-saving therapies and enhancing patient outcomes globally. With an expanded portfolio covering virology, oncology, cell & gene therapy, and more. The best of both worlds with integrated central and specialty laboratory biomarker solutions. Join us in celebrating this milestone and find out more about our transition by visiting: https://lnkd.in/e5Egk95H
Intrested for the Java developer opening
Chief Commercial Officer at Calyx-IRT
4moGood luck with the brand flip at World Vaccine Congress. Great step forward.